The record
| Class | neuropeptide |
|---|---|
| Also known as | Delta Sleep-Inducing Peptide, Emideltide, Deltaran, DSIP nonapeptide |
| Chain length | - |
| Molecular weight | 848.81 Da |
| Half-life | ~15 minutes in vitro |
| Route | IV, intranasal (research) |
| Studied for | Insomnia (investigational); Sleep disorders; Stress reduction; Pain management |
| Research use | Sleep architecture studies; Circadian rhythm research; Neuroendocrine regulation |
| What has been shown | Promotes slow-wave (delta) sleep; Modulates circadian rhythms; Affects ACTH, LH, and GH secretion; Analgesic properties |
| How it works | Neuropeptide affecting sleep architecture; exact mechanism unclear; may act via NMDA receptors; interacts with MAPK cascade; homologous to glucocorticoid-induced leucine zipper (GILZ). Found in hypothalamus, limbic system, pituitary. No gene or precursor identified. |
| Patent status | off patent |
| Regulatory status | not approved; research compound |
Blank = not established in the record. Nothing is estimated to fill a gap.
Where it is matched
- Stress Modulation / Calm State (affection, 50%)
- Sleep Optimization (affection, 86%)
- Circadian Rhythm Alignment (affection, 81%)
- adaptation disorders (illness, 30%)
- anxiety disorders / anxiety states (illness, 30%)
- astheno-neurotic states (illness, 30%)
- Bone pain from metastases (illness, 30%)
- Hypercalcemia (illness, 30%)
- Insomnia (illness, 100%)
- Paget's disease of bone (illness, 30%)
- Pain management (illness, 100%)
- Sleep disorders (illness, 100%)
- Stress reduction (illness, 100%)
- Pain (symptom, 50%)
- Poor sleep (symptom, 100%)
- Anxiety or stress (symptom, 67%)